Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

A growing number of options—from manufacturer discounts to trusted online pharmacies—can help you access Mounjaro affordably ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

A North Texas woman with a cautionary tale warns others to do their research before starting popular weight loss drugs.

A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the drugs’ ability to ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...